Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Fiche publication
Date publication
mai 2024
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr DESMOULINS Isabelle, Dr HENNEQUIN Audrey
Tous les auteurs :
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY
Lien Pubmed
Résumé
Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer after ≥2 anti-HER2-based regimens received at metastatic stage.
Mots clés
HER2‐positive, breast cancer, early‐access program, metastatic cancer, trastuzumab deruxtecan
Référence
Cancer Med. 2024 05;13(9):e7168